Children and young adults aged 7-20 years with congenital hypoparathyroidism ( N = 12 ) were randomized to receive PTH 1-34 , delivered either by twice-daily subcutaneous injection or insulin pump for 13 weeks , followed by crossover to the opposite delivery method .